Compare Best Buy Co Inc (BBY) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs TransMedics Group Inc — how do they compare? Best Buy Co Inc trades at $82.96 (market cap $17.55B), while TransMedics Group Inc trades at $86.89 (market cap $3.10B). The key difference: Best Buy Co Inc is far larger — about 5.7× TransMedics Group Inc's market cap, and Best Buy Co Inc pays a 4.61% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| BBY | TMDX | |
|---|---|---|
Market Cap | $17.55B | $3.10B |
Sector | Consumer Cyclical | Technology |
52-Week High | $90.17 | $150.42 |
52-Week Low | $55.52 | $61.99 |
Enterprise Value | $19.93B | $3.49B |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BBY trades at $83.24, up 0.98% on the day, near the consensus price target of $84.31. The stock shows a neutral technical signal with bullish moving averages. Recent earnings have consistently beaten estimates, and the company maintains solid profitability with a 39.1% ROE. Leadership changes, including a new CFO, and store format tests aim to drive future growth amid declining revenues.
The outlook is mixed: strong cash flow improvement and shareholder returns via dividends support upside, but revenue declines and competitive pressures pose risks. Analysts are cautious with a 'Hold' majority. Investors should weigh valuation attractiveness against execution challenges in a tough retail environment.
TransMedics Group (TMDX) trades at $87.42, down 1.12% on the day, with a bullish technical outlook from moving averages but bearish oscillators signaling potential overbought conditions. The company reported mixed Q2 2026 results, missing earnings estimates with EPS of $0.44 versus $0.50 expected, while revenue growth remains robust. Recent news highlights an ongoing investigation into fiduciary duties by directors, adding uncertainty.
The stock presents a cautious opportunity with strong analyst support (69% buy ratings) and a consensus price target of $99.57, implying upside, but risks include earnings volatility, margin pressures, and legal scrutiny. Fundamentals show solid profitability with a 22.69% net margin, though valuation multiples like P/E of 23.15 suggest premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
